×
Abeona Therapeutics EBITDA 2010-2024 | ABEO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Abeona Therapeutics ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Abeona Therapeutics EBITDA 2010-2024 | ABEO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Abeona Therapeutics ebitda from 2010 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$174.8B
Vertex Pharmaceuticals (VRTX)
$133.1B
Gilead Sciences (GILD)
$120.2B
Bristol Myers Squibb (BMY)
$109.8B
Regeneron Pharmaceuticals (REGN)
$91B
CSL (CSLLY)
$90.5B
GSK (GSK)
$75.2B
Alnylam Pharmaceuticals (ALNY)
$35.8B
Argenex SE (ARGX)
$35.6B
BioNTech SE (BNTX)
$26.3B
Biogen (BIIB)
$25.2B
Illumina (ILMN)
$24B
BeiGene (BGNE)
$20B
Moderna (MRNA)
$18B
Incyte (INCY)
$16.1B
Genmab (GMAB)
$15.3B
Vaxcyte (PCVX)
$13.3B
Insmed (INSM)
$13.2B
BioMarin Pharmaceutical (BMRN)
$12.8B
Bio-Techne Corp (TECH)
$12.1B
Sarepta Therapeutics (SRPT)
$11.6B
Exelixis (EXEL)
$10.4B
Revolution Medicines (RVMD)
$10.2B
QIAGEN (QGEN)
$10B
Intra-Cellular Therapies (ITCI)
$9.7B
Exact Sciences (EXAS)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.8B
Repligen (RGEN)
$7.9B
Halozyme Therapeutics (HALO)
$7.8B